open access

Ahead of print
Original articles
Published online: 2017-09-13
Submitted: 2017-05-08
Accepted: 2017-07-11
Get Citation

CHA2DS2-VASc score predicts contrast induced nephropathy in patients with ST-segment elevation myocardial infarction who were undergoing primary percutaneous coronary intervention

Gokhan Cicek, Ersin Yıldırım
DOI: 10.5603/KP.a2017.0177

open access

Ahead of print
Original articles
Published online: 2017-09-13
Submitted: 2017-05-08
Accepted: 2017-07-11

Abstract

Background: We aimed to investigate the predictive value of the CHA2DS2–VASc score in the development of Contrast Induced Nephropathy (CIN).

Methods: A total of 2972 patients who had been diagnosed with ST elevation-MI and who had undergone primary coronary angioplasty were included in the study. The patients were divided into 3 groups according to the CHA2DS2–VASc score as low risk (1 point), intermediate risk (2 points) and high risk (≥3 points). The groups were followed-up with regard to CIN development.

Results: The median CHA2DS2–VASc score was significantly higher in the CIN(+) groups compared to the CIN(-) group (3 vs 2, p<0.001). The rate of CIN was 3.32-fold higher in the high-risk group (CHA2DS2–VASc ≥3) compared to the low-risk group (CHA2DS2–VASc =1) (OR 3.32, p<0.001). Age (OR: 1.25, p<0.001), female gender (OR: 1.52, p<0.001), hypertension (OR: 1.50, p<0.001), peak CKMB (OR: 1.15, p<0.001) and the KILLIP score >1 (OR: 4.25, p<0.001) were found to be independent predictors for CIN development.

Conclusions: The CHA2DS2–VASc score is an independent and strong predictor of CIN development in patients with acute ST-elevation MI.

Abstract

Background: We aimed to investigate the predictive value of the CHA2DS2–VASc score in the development of Contrast Induced Nephropathy (CIN).

Methods: A total of 2972 patients who had been diagnosed with ST elevation-MI and who had undergone primary coronary angioplasty were included in the study. The patients were divided into 3 groups according to the CHA2DS2–VASc score as low risk (1 point), intermediate risk (2 points) and high risk (≥3 points). The groups were followed-up with regard to CIN development.

Results: The median CHA2DS2–VASc score was significantly higher in the CIN(+) groups compared to the CIN(-) group (3 vs 2, p<0.001). The rate of CIN was 3.32-fold higher in the high-risk group (CHA2DS2–VASc ≥3) compared to the low-risk group (CHA2DS2–VASc =1) (OR 3.32, p<0.001). Age (OR: 1.25, p<0.001), female gender (OR: 1.52, p<0.001), hypertension (OR: 1.50, p<0.001), peak CKMB (OR: 1.15, p<0.001) and the KILLIP score >1 (OR: 4.25, p<0.001) were found to be independent predictors for CIN development.

Conclusions: The CHA2DS2–VASc score is an independent and strong predictor of CIN development in patients with acute ST-elevation MI.

Get Citation

Keywords

CHA2DS2–VASc Score; Contrast Induced Nephropathy; acute ST-segment myocardial infarction; percutaneous coronary intervention

About this article
Title

CHA2DS2-VASc score predicts contrast induced nephropathy in patients with ST-segment elevation myocardial infarction who were undergoing primary percutaneous coronary intervention

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Ahead of print

Published online

2017-09-13

DOI

10.5603/KP.a2017.0177

Keywords

CHA2DS2–VASc Score
Contrast Induced Nephropathy
acute ST-segment myocardial infarction
percutaneous coronary intervention

Authors

Gokhan Cicek
Ersin Yıldırım

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl